Cargando…
Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261548/ https://www.ncbi.nlm.nih.gov/pubmed/28174493 http://dx.doi.org/10.2147/CEOR.S118835 |
| _version_ | 1782499598760148992 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5261548 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Dove Medical Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-52615482017-02-07 Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] Clinicoecon Outcomes Res Corrigendum Dove Medical Press 2017-01-17 /pmc/articles/PMC5261548/ /pubmed/28174493 http://dx.doi.org/10.2147/CEOR.S118835 Text en © 2017 Ponzetti et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| spellingShingle | Corrigendum Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] |
| title | Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] |
| title_full | Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] |
| title_fullStr | Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] |
| title_full_unstemmed | Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] |
| title_short | Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] |
| title_sort | potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 italian hospitals based on a systematic survey [corrigendum] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261548/ https://www.ncbi.nlm.nih.gov/pubmed/28174493 http://dx.doi.org/10.2147/CEOR.S118835 |